Beam Therapeutics (BEAM) Cash & Equivalents (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash & Equivalents data on file, last reported at $288.3 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 45.39% year-over-year to $288.3 million in Q1 2026; TTM through Mar 2026 was $288.3 million, a 45.39% decrease from a year earlier, with the FY2025 full-year figure at $294.9 million, up 4.6% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $288.3 million, down from $294.9 million in the prior quarter.
• Over the last five years, Cash & Equivalents for BEAM reached as high as $527.9 million in Q1 2025 and fell as low as $156.5 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $281.5 million across 5 years, with a median of $282.0 million in 2024.
• On a YoY basis, Cash & Equivalents climbed as much as 205.24% in 2022 and fell as far as 74.43% in 2022.
• Year by year, Cash & Equivalents stood at $232.8 million in 2022, then soared by 87.27% to $435.9 million in 2023, then slumped by 35.31% to $282.0 million in 2024, then increased by 4.6% to $294.9 million in 2025, then decreased by 2.26% to $288.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $288.3 million in Q1 2026, $294.9 million in Q4 2025, and $268.0 million in Q3 2025.